Stem cell transplant for cardiac conditions

CellProthera specializes in autologous cell therapy, focusing on the regeneration of damaged tissues, particularly cardiac tissue, through the use of CD34+ stem cells. Their flagship product, ProtheraCytes®, is derived from these stem cells, which are harvested from the patient's peripheral blood after mobilization from the bone marrow. This cellular product has demonstrated promising clinical results in regenerating cardiac tissues, especially following severe heart attacks that can lead to chronic heart failure. The company emphasizes the importance of personalized medicine, utilizing the patient's own stem cells to enhance the potential for recovery and improve quality of life.

To support the production of ProtheraCytes®, CellProthera has developed a proprietary technology platform that includes the StemXpand® automated expansion device and the StemPack® disposable kit. This GMP-compliant manufacturing process ensures consistent quality and scalability, allowing for the simultaneous production of therapies for multiple patients. The company’s commitment to innovation in regenerative medicine is further highlighted by their ongoing research into various indications, including ischemic stroke and refractory angina, showcasing the versatility and potential of CD34+ stem cells in addressing significant unmet medical needs.

France

CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans.

CellProthera

Company Details